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AGRICULTURAL BIOTECHNOLOGY: WHY IT CAN SAVE THE
ENVIRONMENT AND DEVELOPING NATIoNs, BuT MAY
NEvER GET A CHANCE
MARY LYNNE KUPCHELLA*
I. INTRODUCTION
Commercial biotechnology is perhaps one of the most important
developments of the last century. Agricultural biotechnology' has the
potential to solve many of the most daunting environmental problems
facing the world, such as a decrease in biodiversity and shortages of food.2
With proper regulation, biotechnology can save biodiversity and solve
numerous other environmental concerns. One expert has noted,
The tools of biotechnology are going to be essential if crop-
yield ceilings are to be raised, the environment preserved
through reduction of pesticide use, the nutrient value of
basic foods increased and farmers on less-favored lands
provided with varieties better able to tolerate drought,
salinity and lack of soil nutrients.
3
Unlike the United States, the European Union (EU) does not
welcome agricultural biotechnology. 4 Its unfounded resistance threatens
* Ms. Kupchella received her B.A. in Biology from Franklin & Marshall College in 1998
and expects to receive her J.D. from the College of William & Mary School of Law in
2001.
1 The U.S. Dep't of State defines "agricultural biotechnology" as "a collection of
scientific techniques, including genetic engineering, used to create, improve, or modify
plants, animals, and microorganisms." U.S. Dep't of State, Biotech Basics, at
http://usinfo.state.gov/topical/global/biotech/99120101.htm (Dec. 1, 1999).
2 Dan Glickman, New Crops, New Century, New Challenges: How Will Scientists,
Farmers, and Consumers Learn to Love Biotechnology and What Happens if They
Don't?, Remarks Before the National Press Club, at http://www.uada.gov/news/releases/
1999/07/0285 (July 13, 1999).
3 Gordon Conway, Biotech Can Feed the World, or Divide It, PLAIN DEALER (Cleveland,
OH), Oct. 19, 1999, at 9B.
4 See Glickman, supra note 2.
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the realization of the full potential of biotechnology. 5 While there are
potential risks to agricultural biotechnology, and the long-term effects are
unknown, the benefits of this technology are immense.6 If these benefits
are to be realized, a worldwide effort is required. Many issues threaten to
impede the potential of biotechnology, but none are insurmountable. 7
This paper will outline some of the major issues surrounding the
agricultural biotechnology debate. Part I will discuss the benefits and
potential risks of this technology in order to show what immense potential
exists for biotechnology to solve many environmental problems. Much of
the dispute concerning this subject exists because of the differing views of
the United States and the EU. In Part II, the U.S. regulatory network for
biotechnology will be compared to that of the EU to provide a background
for these differences. Part III will briefly discuss the effects of the
biotechnology debate on international trade. Intellectual-property rights
play a large part in this equation and represent another area where the EU
and United States tend to differ. The policies and systems of the
developing and developed nations do not agree on intellectual-property
issues either. Part IV will discuss the Convention on Biological Diversity8
(Convention), the most recent attempt at an international agreement to
solve the foregoing issues. The Convention seems to be a general step in
the right direction; however, most are not confident that an agreement will
ever be reached between the member nations. Through this treaty, nations
of the world have recognized that maintaining biological diversity is an
issue that must be addressed. However, it steps in the wrong direction by
attempting to erode intellectual-property rights. Its goals can be
accomplished by other means.
Finally, in Part V, this paper concludes that agricultural
biotechnology can, with the cooperation of every nation, solve serious
environmental issues. If those countries with opposing views are further
polarized, however, biotechnology cannot reach its potential. Currently,
developing nations are in desperate need of aid from the developed
nations. Agricultural biotechnology will solve many of their problems,
but can only do so effectively with support from the EU. Differences must
be set aside, as must political influences, to aid those less fortunate. While
5 Dennis T. Avery, Europe Engaged in a Phony War on Biotechnology, BRIDGE NEWS,
July 15, 1999.6 See Conway, supra note 3, at 9B.
7 See id.
8 United Nations Conference on Environment and Development: Convention on




third-world nations are currently the most in need, the entire world's
population relies on the biodiversity found mainly in the developing
nations. Even if the EU is unwilling to accept agricultural biotechnology
for its citizens, it must realize the good it can do in other areas of the
world.
II. THE BACKGROUND OF AGRICULTURAL BIOTECHNOLOGY
Biotechnology is defined by the United Nations as "any
technological application that uses biological systems, living organisms, or
derivatives thereof, to make or modify products or processes for specific
use."9 The most commonly known biotechnology techniques are those of
recombinant DNA technology, which the public refers to as "genetic
engineering."' 01 The genetic material that is derived from the world's
diverse resources is a basic source for biotechnology.1" At the same time,
however, biotechnological products affect the biodiversity within the
ecosystems into which they are introduced. 12 Many believe that as the use
of biotechnology has risen, a related loss of biodiversity has occurred.
13
Seeds have been historically transferred around the world, most commonly
from the genetically rich, less-developed countries into the genetically
poor, developed countries.' 4
9 Id. art. 2, at 823.
10 Dan L. Burk, A Biotechnology Primer, 55 U. Pir. L. REv. 611, 616 (1994). Bcterial
enzymes called nucleases cut a chain of DNA at a previously defined base-pair sequence.
Additional enzymes known as ligases then reconnect the cut DNA strands. By using this
basic technique, DNA can be formed into new sequences. This recombinant DNA must
then be transferred into a host cell where it can express itself. DNA is often introduced
through a "vector." See id. at 616-617.
" Curtis A. Bradley, Introduction to Biodiversity and Biotechnology, 7 COLO. J. INT'L
ENVTL. L. & POL'Y 107, 107 (1996).
2 See id.
13 Klaus Bosselmann, Plants and Politics: The International Legal Regime Concerning
Biotechnology and Biodiversity, 7 COLO. J. INT'L ENVTL. L. & POL'Y 111, 111 (1996).
The term "biodiversity" refers to the diversity of life on Earth. This concept can refer to
the diversity of species, the diversity within species, and the diversity of ecosystems.
Biodiversity can be lost through deforestation as well as gene erosion and gene
uniformity. See id. at 112-114.
14 Id. at 116.
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A. The Benefits ofAgricultural Biotechnology
In order to understand the implications of agricultural
biotechnology, one must understand its principal benefits and risks. Many
environmental and health benefits may be realized through the use of
agricultural biotechnology. In agriculture, the targets for increased control
are resistances to weeds, insects, disease, temperature fluctuations, and
instability of the water supply. 15 The use of biotechnology has grown
steadily in the United States. 16 In 1998, genetically engineered crops
accounted for 25% of corn acreage planted in the United States, 38% of
soy bean acreage, and 45% of cotton acreage, for a total of 45 million
acres, an increase of 250% from 1997.1' In 1999, "biotechnology
,,18plantings in the U.S. increased to 62 million acres ....
The production of crops which exhibit herbicide resistance is one
of the more "controversial applications of biotechnology to agriculture."'
19
Herbicide-resistant crops are most attractive to industry, however, as
herbicide expenditures have risen steadily over the past fifteen years.
20
Plants exhibit various levels of tolerance to herbicides and some can be
damaged or even killed by very low doses. 21  The use of herbicide-
resistant crops will likely cause a reduction in the quantities of herbicides
used.22 Herbicides may be applicable in stronger doses and multiple
herbicide treatments may be replaced by the use of a single herbicide,
resulting in a reduction in the number of applications and quantity used.23
Additionally, herbicide-resistant crops may be able to promote integrated
management of weeds by causing a shift to a total post-emergence
approach to weed control.24 Proponents of resistant crops also believe that
15 See David R. Purnell, International Implications of New Agricultural Biotechnology,
25 U. MEMPHIS L. REv. 1189, 1192 (1995).
16 See U.S. Dep't of State, supra note 1.
"7 Id. Worldwide, 69 million acres of genetically engineered crops were planted in 1998.
Id.
18 David Barboza, Redesigning Nature: In the Heartland, Genetic Promises, N.Y. TIMES,
Mar. 17, 2000, at Cl.
19 SHELDON KRIMSKY & ROGER P. WRUBEL, AGRICULTURAL BIOTECHNOLOGY AND THE
ENVIRONMENT 29 (1996).
20 See id. at 30-31.
21 See id. at 33-34.
22 See id. at 41.
23 See id. at 42.
24 See id. at 42. Herbicides are most often applied to fields before the crops begin to
grow. Treating crops "post emergence" is difficult to do effectively without harming the
crop. If herbicide-resistant crops are effective, herbicides would potentially be needed
[Vol. 25:721724
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they will allow older, more toxic and generally more harmful herbicides to
be replaced with ones which are more environmentally favorable.25
Those who oppose the use of herbicide-resistant crops generally
hold the opinion that herbicides have detrimental effects on the
environment.26 While many effects of herbicides may be yet unknown,
they do possess well-demonstrated benefits.27 The most serious concern,
however, is that weeds will rapidly develop a resistance to the few
herbicides currently relied upon.2" Also, herbicide-resistant crops are not
being designed to solve problems in the areas of the world where they are
most greatly needed.29 Many of the products being developed are not
necessarily relevant to agriculture in developing countries. Developing
countries will have to integrate modem biotechnology with their own
research.3°
Aside from greater environmental benefits, agricultural
biotechnology provides much hope for many problems faced by
developing or third-world nations. In developing countries, an increase in
the quality and volume of agricultural production is greatly needed.31 The
potential of biotechnology in allowing the rapid development of new crop
only if the crops fail to provide adequate control on their own. See id; see also Lidia S.
Watrud, et al., Engineered Plants in the Environment, in ENGINEERED ORGANISMS IN
ENVIRONMENTAL SETTINGS: BIOTECHNOLOGICAL AND AGRICULTURAL APPLICATIONS,
165, 171 (Morris A. Levin & Eitan Israeli eds., 1996).
25 See KRIMSKY & WRUBEL, supra note 19, at 44.
26 See id. at 45.
27 See id. at 44. Prior to the widespread use of herbicides, weeds were controlled through
the frequent cultivation of the soil. Such activity compacts the soil and causes high
amounts of erosion. See id.
28 See id. at 46; see also Stephen 0. Duke, Weed Management: Implications of Herbicide
Resistant Crops, Paper Presented at the Workshop on Ecological Effects of Pest
Resistance Genes in Managed Ecosystems, at http://www.nbiap.vt.edu (Jan. 31 to Feb. 3,
1998) ("[E]nvironmentalists are concerned with the potential impacts of gene flow from
transgenic crops to wild relatives [however] herbicide resistance transgenes confer no
fitness advantage outside of fields treated with the herbicide.").
29 See KRIMSKY & WRUBEL, supra note 19, at 50. The crops that are being genetically
engineered are those which are most profitable in developed nations. A great need exists
to control weed problems in third-world nations where weeds can "yield losses of up to
fifty percent." Id. "Genetically modified plants have the potential to resist killer weeds
that are, literally, starving people in Africa and other parts of the developing world."
Glickman, supra note 2.
30 See Carliene Brenner & John Komen, International Initiatives in Biotechnology for
Developing Country Agriculture: Promises & Problems, at http://www.oecd.org//ehs/
icgb/biopubs.htm (last modified Nov. 24, 1999).
31 See Carliene Brenner, Biotechnology in the Developing World.- Lessons from Maize,
OECD OBSERVER, Aug. 1991, at 9.
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varieties and hybrids that are resistant to stresses such as soil salinity and
drought could be an important step towards meeting the needs of
subsistence farmers.32 Such farmers are largely unable to afford the costly
inputs on which past advances in agriculture have been based, so their
crops have until quite recently been neglected by research.33 Africa
particularly needs agricultural biotechnology to improve food production
as well as its agricultural problems.34 Biotechnolov, will also be able to
solve nutritional deficiencies in developing nations. Approximately 400
million women suffer from iron deficiency in third-world nations where
the staple diet is rice.36 A new variety of rice containing iron and vitamin
A will be able to decrease this number.37 However, the availability of
biotechnology to third-world nations, while highly desirable and
necessary, is subject to intellectual property and production concerns,
which will be addressed in Part 111.31
The economic benefits of "more efficient, higher yielding, higher
quality, disease- and stress-resistant crops and livestock are evident."
39
Crops that exhibit disease resistance have an enormous potential as the
annual worldwide loss from plant disease is estimated at ninety billion
dollars. 40 The most obvious environmental benefit of resistant plants
would be a reduction in fungicides.41 By reducing the amount of crops
lost each year to disease, fewer acres may need to be planted, thus
32 See Florence Wambugu, Why Africa Needs Agricultural Biotech, NATURE, July 1,
1999, at 15-16. "On about half the arable land in the tropics, acid soils cut yields by up to
eighty percent." Avery, supra note 5. However, acid-soil crops provide normal yields in
s ite of soil acidity. Id.
3 See, e.g., Wambugu, supra note 32, at 15.
34 See id. (stating that "Africa's crop production per unit area of land is the lowest in the
world"). Africa also needs biotechnology to solve environmental problems. For
example, "[i]n Kenya the demand for tree seedlings reaches 14 million per year" and "the
country can only supply 3 million." Id. at 16. Tissue-culture and cloning techniques are
desperately needed to "curb deforestation and boost reforestation using indigenous
PIecies threatened with extinction." Id.Today, in developed nations, supplements are routinely added to the diets of animals
such as chicken to provide nutrients such as methionine or lysine. See Watrud, supra
note 24, at 173.36 Conway, supra note 3.
37 Id.
38 See Purnell, supra note 15, at 1197-1199.
39 1d. at 1192.
40 See KRIMSKY & WRUBEL, supra note 19, at 87.41 See id. at 89.
726 [Vol. 25:721
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providing the benefits associated with a reduction in agriculture.42 The
possibility exists that disease resistant plants may pose environmental
risks; however, such risks are only potential and even the Environmental
Protection Agency (EPA) does not regard them as significant.43
The production of insect-resistant crops will have similar
advantages. Transgenic plants that produce insect toxins are environment-
ally friendly because they will not have to be sprayed with insecticides. 44
The problems caused by insecticides are well known and include toxicity
to humans and animals.45 Crops are also currently being developed which
can be grown in poor soil conditions and which will require less water.46
"Stress-tolerant plants" are also being developed which have the capability
to extend "agricultural possibilities to marginal lands," providing a
"powerful benefit to poor farmers. '' 47
Higher-yielding crops are yet another way in which biotechnology
will aid agricultural output. By the year 2050, the world will need almost
three times the amount of grain per year as it uses today.48 Crop yields
have ceased to grow as rapidly as needed to keep pace with population
increases.49 Additionally, the percentage of the population working in
agriculture has steadily declined.50 If higher-yielding crops are not used,
wild lands will have to be used for agriculture.5 ! On the other hand, if the
same product can be produced with less cultivated land, then more land
can be returned to a natural habitat..2 Genetically modified crops will also
42 See id. "Increased yields in third, world countries would help achieve food self-
sufficiency and improve the standard of living, gaining many indirect environmental
benefits." Id.
41 See id. at 95. "[T]he Environmental Protection Agency does not regard the risks
associated with the development of genetically engineered crops resistant to viruses as
significant." Id. A high likelihood exists, however, that virus strains will develop to
circumvent any genetically engineered resistance and that new diseases will be created
when viruses replicate in transgenic plants. See id. at 89-94.
" See id. at 61.
45 See id. at 55. Secondary pest outbreaks, which may cause disruptions in the food
chain, are often caused by the killing, of beneficial insects. Id. The widespread use of
insecticides has also caused a strong selection pressure for the evolution of insecticide
resistance in insects. Id. at 63.
4See Purnell, supra note 15, at 1192.
47 Glickman, supra note 2.
4See Avery, supra note 5.
49 See id.
50 See KRIMSKY & WRUBEL, supra note 19, at 213.
51 See Avery, supra note 5.52 See KRIMSKY & WRUBEL, supra note 19, at 237.
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result in land that needs less tilling, benefiting the environment through
decreased erosion and soil infertility.
53
B. Potential Risks ofAgricultural Biotechnology
While the benefits of biotechnology are numerous and promising,
risks are also evident. Most concerns exist, however, because of the
unknown consequences of biotechnology.5 Historically, problems have
existed when non-native species were artificially introduced into55
ecosystems. Some fear that biotechnology may be too successful and
will lead to an over-production of key crops.5 6 It is also possible that
newly introduced traits, such as pest or pathogen resistance, could confer
added fitness to a crop, and as a result, the crop could gain weedy
characteristics.5 7 Yet unknown is what types of interactions genetically
modified plants will have with other species. There is a fear that
genetically altered organisms will become agricultural pests or colonize
natural ecosystems, disturbing balances, especially where characteristics
would allow it to compete successfully.5 8  It is possible that these new
organisms will hybridize with a related wild species thereby producing
hybrid progeny that are harder to control.5 9  Even plants which are
unlikely to escape into the wild can potentially change populations of
microorganisms in the soil and the types and numbers of insects and other
animals in surrounding areas.6°
53 See Donna U. Vogt & Mickey Parish, Food Biotechnology in the United States:
Science, Regulation, and Issues, at http://usinfo.state.gov/topical/global/biotech/
crsfood.htm (June 2, 1999) (stating that industries contend that the U.S. regulations are
more than adequate to ensure human safety and health).
5 See Purnell, supra note 15, at 1193.
55 See id.
56 See Al Gore, Planning a New Biotechnology Policy, 5 HARV. J.L. & TECH., Fall 1991,
at 19, 28-29.
57 James H. Westwood & Patricia Traynor, Executive Summary, Paper Presented at the
Workshop on Ecological Effects of Pest Resistance Genes in Managed Ecosystems, at
http://www.nbiap.vt.edu (Jan. 31 to Feb. 3, 1998); cf Carol K. Yoon, When
Biotechnology Crops and Their Wild Cousins Mingle, N.Y. TIMES, Nov. 3, 1999, at A 18
(discussing concern that "genes from these plants could escape into wild plants by
interbreeding").
58 See David J. Earp, Comment, The Regulation of Genetically Engineered Plants: Is
Peter Rabbit Safe in Mr. McGregor's Transgenic Vegetable Patch?, 24 ENVTL. L. 1633,
1653-54 (1994).
59 See id. at 1654. At least seven groups of crops being engineered for pest resistance are
known to have sexually compatible relatives. See Westwood & Traynor, supra note 57.
60 See Watrud et al., supra note 24, at 178.
[Vol. 25:721728
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Crops engineered to be pest resistant will be ineffective if the
insects develop a resistance to the toxin in the plant. However, with
cooperation between growers and regulatory agencies, potential problems
such as this need not become issues.6' Some researchers are also
concerned about potential virus resistance of modified plants and fear that
hybrid viruses may be formed.62
A substantial concern exists over the potential loss of biological
diversity.63 Biotechnology research relies heavily on biodiversity, and as
such this diversity needs to be preserved. 64 Biodiversity is lost through
deforestation as well as through gene erosion and gene uniformity.65 The
greatest threat to biodiversity is loss of habitat to "nonsustainable and/or
61 In 1999, around thirty percent of com grown in the United States was Bt (Bacillus
thuringiensis) corn, which contains bacteria that kill the European corn borer. The EPA
is now requiring farmers to plant a minimum of twenty percent of conventional corn in
most areas, and fifty percent in places where cotton is grown. Planting conventional
crops beside Bt crops will allow the non-Bt plants to attract pests so they will not develop
resistance. The pests will then interbreed and thus reduce the likelihood that resistance to
the Bt plants will develop. Companies will also be required to expand monitoring to
determine where insect resistance may be occurring. See Philip Brasher, New
Restrictions on Biotech Corn, THE ADVOCATE (Baton Rouge, La.), Jan. 17, 2000, at 9-A.
62 See Earp, supra note 58, at 1655. Plants which are made "resistant to certain virus
types by transformation with viral coat protein genes may provide an environment for
interactions between the introduced genes and other virus types." Id.
63 Purnell, supra note 15, at 1194; see Convention, supra note 8, art. 2, at 823 (defining
biological diversity as "the variability among living organisms from all sources including,
inter alia, terrestrial, marine and other aquatic ecosystems and the ecological complexes
of which they are part; this includes diversity within species, between species and of
ecosystems"); see also Michele A. Powers, Comment, The United Nations Framework
Convention on Biological Diversity: Will Biodiversity Preservation Be Enhanced through
Its Provisions Concerning Biotechnology Intellectual Property Rights?, 12 Wis. INT'L
L.J. 103, 103 (1993) (stating that studies estimate that a ten percent reduction in
biodiversity will occur in the next twenty-five years).
6 See Purnell, supra note 15, at 1195; see generally Peter H. Raven & Jeffrey A.
McNeely, Biological Extinction: Its Scope and Meaning for Us, in PROTECTION OF
GLOBAL BIODIVERSITY 13, 26-28 (Lakshman D. Guruswamy & Jeffrey A. McNeely,
eds., 1998) (discussing the ecological reasons that people should be "concerned with the
loss of biodiversity").
65 See Bosselmann, supra note 13, at 113-114. Some believe that monocropping
("planting a uniform type of crop across a large area") could cause a reduction in genetic
diversity. Purnell, supra note 15, at 1194. Farmers tend to "choose the most productive
varieties," thus resulting in a decline in the overall number of varieties used. However,
such a result is not caused by genetic engineering, but by the desire of the farmer to
produce the greatest amount possible. See id.
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low productivity agriculture."'' By increasing net agricultural product-
ivity, biotechnology will aid in protecting natural habitats.
67
This paper argues that the potential risks are minimal in
comparison to the extreme benefits that agricultural biotechnology can
provide. One of the strongest arguments for the regulation of transgenic
food concerns the spread of allergenicity throughout the food supply.
However, such concerns are more prominent in the EU than in the United
States and will be discussed in greater detail in Part I.
Those opposed to agricultural biotechnology are drawn from
several different fields, but include three primary sources: the agricultural
community, environmentalists and the moral opposition.68  Many
environmentalists are obviously opposed and have been waging war with
the biotech companies for quite some time.69  Some farmers are also
opposed to biotechnology. They believe they cannot afford to utilize
agricultural biotechnology and that expensive products will drive small
farmers out of business.70  They also believe that enhanced crop
production will saturate the market, thereby causing profits to decline.71
Additionally, there is a moral opposition not only to agricultural
biotechnology, but to any form of biotechnology whatsoever.72
III. REGULATION OF BIOTECHNOLOGY
A. Regulation in the United States
No statutes exist in the United States that address biotechnology
specifically.73 However, there is a very comprehensive process to evaluate
genetically modified products for risks to human, animal, and plant health
6 Robert B. Horsch & Robert T. Fraley, Biotechnology Can Help Reduce the Loss of
Biodiversity, in PROTECTION OF GLOBAL BIODIVERSITY, supra note 64, at 49.
67 See id. at 50. But see Laura L. Jackson, Agricultural Industrialization and the Loss of
Biodiversity, in PROTECTION OF GLOBAL BIODIVERSITY, supra note 64, at 66 (arguing
that biotechnology products will endanger remaining biodiversity).
68 See David G. Scalise & Daniel Nugent, Patenting Living Matter in the European
Community: Diriment of the Draft Directive, 16 FORDHAm INT'L L.J. 990, 995 (1993).69 See id.
70 See Purnell, supra note 15, at 1197.
71 See id.
72 See id.
73 See Terence P. Stewart & David S. Johanson, Policy in Flux: The European Union's
Laws on Agricultural Biotechnology and Their Effects on International Trade, 4 DRAKE
J. AGRIC. L. 243, 247 (1999).
[Vol. 25:721730
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and for environmental safety.74 The U.S. Department of Agriculture
(USDA) and the EPA are primarily responsible for regulating the release
of transgenic plants.75 The EPA regulates the minority of engineered
plants which may have pesticidal properties as defined by the Federal
Insecticide, Fungicide, and Rodenticide Act.76  The USDA's authori
comes from the Federal Plant Pest Act 77 and the Plant Quarantine Act.78
By this statutory authority and through the Animal and Plant Health
Inspection Service (APHIS), the USDA is able to regulate the
"introduction of genetically modified organisms." 79
The United States' regulations are not without criticism.8 1 Most
would agree, however, that the present regulatory framework is a "sound
risk-based regulation that both fosters technological development and
protects the environment against known risks."
8
'
B. Regulation in the European Union
While agricultural biotechnology is widespread and accepted by
consumers in the United States,8 2 the EU83 has a far different perspective.
74 See Earp, supra note 58, at 1640 n.36. The USDA, EPA, the Food and Drug
Administration (FDA), the National Science Foundation (NSF), the National Institute of
Health (NIH), and the Occupational Safety and Health Administration (OSHA) all have
,urisdiction over products produced by genetic engineering. See id.
See id. at 1637.
76 7 U.S.C. §136 (1988 & Supp. V. 1993); see Earp, supra note 54, at 1641.
777 U.S.C. § 150aa-150jj (1988 & Supp. V 1993).
78 7 U.S.C. §151-64, 166-67 (1988).
'9 Arnold S. Foudin & Cyril G. Gay, Introduction of Genetically Engineered
Microorganisms into the Environment: Review under USDA, APHIS Regulatory
Authority, in ENGINEERED ORGANISMS IN ENVIRONMENTAL SETTINGS, supra note 23, at
85, 86; see also Stewart & Johanson, supra note 73, at 249-250. APHIS primarily
regulates genetically modified organisms (GMOs) that may become plant pests. If
APHIS determines that a genetically modified organism is not a plant pest, it will
deregulate it and thus allow it to be planted. See id.
go See Carol K. Yoon, Redesigning Nature: A Special Report; Squash With Altered Genes
Raises Fears of 'Superweeds,' N.Y. TIMES, Nov. 3, 1999, at Al (stating that the USDA
has not rejected a single application for a genetically engineered crop).
81 Earp, supra note 58, at 1671; see Vogt & Parish, supra note 53.82 See Stewart & Johanson, supra note 73, at 246; Ambassador Peter Scher, Trade Policy
& The Scientific Revolution: The Case of Agricultural Biotechnology, Address Before
the New York Academy of Sciences, at http://usinfo.state.gov/topical/global/
biotech/99112401.htm (Nov. 19, 1999) (stating that seventy-eight percent of people in the
United States favor the use of biotechnology in agriculture).
83 The member countries of the European Union are: Austria, Belgium, Denmark,
Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, the Netherlands,
2001]
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For example, of the thirty-five million hectares planted in 1998 of
genetically modified crops, eighty-eight percent were planted in North
America, and less than one percent was planted in Europe. 84 There are
many factors that attempt to account for such a large discrepancy, many
having to do with issues unrelated to biotechnology. In Europe, cultures
vary drastically from country to country and matter greatly, while in the
United States, variations in culture and behavior among regions is less
distinct.8 6 United States industry is much more research oriented than that
of the EU.87 The U.S. government funds a great deal of biotech research
through several agencies, and this funding helps to support a "highly
competitive industrial and regulatory structure." In contrast, government
funding and support in the EU is more bureaucratic and exists on a much
smaller scale.
8 9
The structure of the EU's legislature influences its laws relating to
agricultural biotechnology. 90 The European Commission "acts as the
executive body for the laws... of the European Union."91 The Council of
Ministers is composed of representatives of the member states who work
on behalf of their respective governments. 92 Essentially, the Commission
proposes legislation and the Council determines whether it will be
adopted.93 The European Parliament is the only directly elected body of
government in the EU. Its primary role, however, is an advisory one, as
its legislative power is generally weak.
94
The EU has two major laws directed at biotechnology. The first,
Council Directive 90/220/EEC, "concerns the placing in the market of
Portugal, Spain, Sweden, and the United Kingdom. See John Ashworth, Development of
the European Biotechnology Industry, 33 CAL. W. L. REv. 83, 85 n.5 (1996).
"' B. Zechendorf, Agricultural Biotechnology: Why Do Europeans Have Difficulty
Accepting It?, I AGBIOFORuM 3, 2 (Summer 1998), at http://www.agbioforum.org/
archives.htm.
85 See id. at 3.
86 See id. at 5.
87 See Ashworth, supra note 83, at 88 (the United States devotes 23.4% of its workforce
to research and development while the EU devotes only 13.4%).
88 Id. at 92; see also supra text accompanying note 74.
89 See Ashworth, supra note 83, at 92. A consequence of these differences is that many
large corporations have established laboratories in the United States. See id.
9 See Stewart & Johanson, supra note 69, at 252.
91 Id. The twenty members are to act independently of their national governments to
further the interests of the EU. See id.





GMO products that may be described as raw materials."9 Under this
Directive, there is a notification process for placing a genetically modified
organism (GMO) on the market.96  It requires notification of the
manufacture or importation of a GMO. The Directive also contains
labeling amendments. 90/220 has essentially broken down, as "[flor over
two years, no products have been approved.
9 7
Regulation No. 258/97 applies to placing novel foods on the
market, including foods containing GMOs.98 This Regulation specifies
that food containing GMOs, as well as foods that were produced by
genetic techniques, must be labeled accordingly. 99 Despite regulatory
attempts by the EU, member nations have individually prohibited the use
of GMOs that had been approved by the Commission. I°° In fact, Directive
90/220 allows a member state to "provisionally restrict" a product it has
justification to believe causes risks to health or the environment.' 0' In
contrast with the United States, companies introducing foods derived
through biotechnology in the EU must obtain approval.
102
The EU has been extremely slow to match scientific advances with
the necessary related policy and regulatory adjustments.'0 3  Transgenic
9' Id. at 256. A Directive obligates the legislatures of each member state to conform their
laws to objectives established by the EU. Id. at 255. This regulation also requires
notification before placing a GMO on the market. The Commission evaluates potential
risks and decides if the GMO is authorized. See Raymond O'Rourke, Genetically
Modified Foods, 147 NEW L.J. 1578, 1578 (1997).
9 A dossier must be submitted to the Commission which decides on the application
following an evaluation of the risks involved in placing the GMO on the market. When
the GMO is authorized, it can be freely circulated in the EU. However, it can be
temporarily prohibited if a member state believes that it is a possible danger to public
health or the environment. As of October 1998, five of the EU member states had
imposed bans on some form(s) of GMOs. See Pierre-Benoit Joly & St phane Lemari6,
Industry Consolidation, Public Attitude and the Future of Plant Biotechnology in Europe,
1 AGBIOFORUM 10, 2 (Fall 1998), at http://www.agbiofonim.org/archives.htm
97 Ambassador David L. Aaron, Under Secretary of Commerce for Trade, Remarks
Before the Conference on Biotechnology: The Science and the Impact, at
http://www.ita.doc.gov/media/eurol23speech.htn (Jan. 21, 2000).
98 See Stewart & Johanson, supra note 73, at 256. A regulation applies throughout the
entire EU as soon as adopted. Thus, each nation does not have to individually implement
the legislation. See id. at 255-56.
99 See O'Rourke, supra note 95, at 1579. Foods must be labeled if, after scientific
assessment, it is shown that they are no longer equivalent to traditional foods.
'0o See, e.g., Stewart & Johanson, supra note 73, at 266-67 (discussing the banning of Bt-
Maize by Austria and Luxembourg).
101 See id. at 259-60.
'
02 See id. at 248.
103 See Vogt & Parish, supra note 53.
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crops should undergo rigorous regulations, but if found to be safe, they
should be used. 1' 4 Other nations watch the policies of the United States
and the EU with great interest. If the EU begins to influence such nations
on biotechnology issues, such influence will only be harmful to global
issues.1 0 5 The EU seems to want a comprehensive regulation, but does not
know what such a regulation should be and is hampered by its slowness to
change.1
0 6
Negative public opinion has had a most harmful effect on the
acceptance of agricultural biotechnology in the EU. 107  The term
"Frankenstein food" has been used to describe GMOs in Europe.08 Much
of the public distrust stems from confusion and lack of education. Such
opinion has caused an "over-concentration... on the regulation of genetic
engineering processes. ' ' 09 U.S. regulations generally concentrate on the
products produced, not the processes.' 10 The commercialization of GMOs
arrived in Europe following two major health crises."1 ' These crises have
had several longstanding effects. "[T]hey have created distrust of public
regulation and expertise" and of public institutions. 112 European citizens
104 In the EU, before a crop can be field tested or released, a license or consent must be
obtained from a member government. See id.
05 See Genetic Id's New GMO Tests Can Save US. Corn Exports to Japan," Restore
Exports to Europe, at http://news.excite.com/news/bw/000323/ia-genetic-id (last
modified Mar. 23, 2000) [hereinafter Genetic Id's].
106 See Vogt & Parish, supra note 53.
107 See David Barboza, Biotech Companies Take on Critics of Gene-Altered Food, N.Y.
TIMES, Nov. 12, 1999, available at http://www.nytimes.com/library/national/science/
11 1299sci-biotech-gm.html (most opponents to this technology believe that not enough
research has been done to prove that food made from GMOs is safe); see also Stewart &
Johanson, supra note 73, at 246-47. One recent poll in England showed that only one in
100 people thinks that genetically modified products are good for society. See John
Micklethwait, Life by Design: Europe's Profound Fear of Food, N.Y. TIMES, June 7,
1999, at A23.
108 See Micklethwait, supra note 107, at A23.
109 Ashworth, supra note 83, at 93-94.
"
0 See id. at 94.
111 See Joly & Lemari6, supra note 96, at 14. These health crises were contaminated
blood and the outbreak of mad cow disease. See id. "Mad-cow" disease, or bovine
spongiform encephalopathy, "is a brain disease that affects beef and dairy cattle."
Ashworth, supra note 83, at 93 n.23. In 1996 nearly every country in the EU imposed
bans on importing British beef. Id. at 94 n.23. Later in that year the European
Commission imposed a world-wide ban "on the exporting of British beef." Id. (citing
John Darnton, Europe Orders Ban on Exports of British, N.Y. TIMES, Mar. 28, 1996, at
A1).
112 Joly & Lemari6, supra note 96, at 14.
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do not trust the government to regulate any types of food. 113  GMOs
became a politically risky topic, with most policy makers bypassing the
issue. 14 The public also does not have an accurate understanding of the
current state of agriculture and does not understand the utility of new
technology."'
In order for government regulations to guarantee public health and
environmental safety, they must be science-based and free of political
influence. 1 6 The EU seems to say that until it can be proven that there
will never be a risk from GMOs, they should not be introduced." 7 That,
however, is an extremely unrealistic standard."i8
Unfortunately, opposition to GMOs seems to be increasing in the
United States.' 19 If fear spreads in the United States, it is likely that an
increasing number of companies will move away from genetically altered
crops.
IV. TRADE AND INTELLECTUAL PROPERTY ISSUES
A. Trade
"The United States and the European Union share the world's
largest trading relationship."' 20  One of the greatest areas of conflict
between them is agriculture, particularly agriculture involving
biotechnology. 12  The United States believes that the EU's policies are a
barrier to trade. Economically, the EU is at a competitive disadvantage
with the U.S. biotechnology industry. Because of the EU's approval
system for GMOs, the United States has had great trouble expanding into
EU markets.
22
113 See Aaron, supra note 97.
114 See id.
115 See id.
116 See Scher, supra note 82.
117 See id.
11S See id.
19 Protests are starting to occur in the United States over the safety of genetically
modified foods. Some food producers have stated that they will not use biotechnology
crops. McCain Foods will not use altered potatoes, Frito-Lay will not use modified corn,
and Gerber will not use biotech crops in its baby food. See Barboza, supra note 18, at
C6.
120 Stewart & Johanson, supra note 73, at 246 (citation omitted).
121 See id.
122 Some believe that the EU is using this time to build its own biotech industry. See
Vogt & Parish, supra note 53. But see Bosselmann, supra note 13, at 128 (stating that
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Labeling all products containing GMOs, as desired by the EU,
would require "separate distribution systems for GMO and non-GMO
products" and be impracticable for exporters. 123 There are also problems
for imports as no major trading partners of the EU have the same
policies.'
24
Biotechnology products are not directly covered by the World
Trade Organization (WTO) agreements, and thus it is not clear which
agreements would cover disputes concerning agricultural biotechnol-
ogy. 25  It is possible that the policies of the EU may not "comport with
its obligations under the WTO.' 126
The fear of GMOs in other parts of the world is having a profound
impact on the exporters of American agricultural commodities. A new
Japanese regulation, to be enforced starting April 1, 2001, bans imports of
"unapproved genetically modified corn varieties for human
consumption. ' ' 127 Japan is currently the largest export market for U.S.
corn, a figure that could decrease dramatically with such a regulation of
genetically modified corn. 128 GMO regulations in other areas of the world
will likely cause the United States major difficulties. The amount of
genetically modified crops planted in the United States has increased
steadily because of the numerous benefits these provide, but if a market
does not exist elsewhere, they will not be profitable.
B. Intellectual Property Concerns
In the nineteenth century, it was thought that biological inventions
were not eligible for patent protection. 29 From 1925 to 1934, the Paris
Convention was revised to include biotechnological products; however, it
did not expressly include plants.' 30 It was, however, difficult to obtain
many European biotech companies are considering moving to the United States to take
advantage of the more liberal view of biological patents in the United States).
123 Stewart & Johanson, supra note 73, at 277-78.
124 See id. at 278.
121 See id. at 287.
126 Id. at 293. As an example, the EU has only approved four of eleven GMO corn
varieties for import. But the EU has not taken any official action, so the United States
cannot yet formally protest under the WTO. See Vogt & Parish, supra note 53.
127 Genetic Id's, supra note 105.
128 See id. Currently Japan buys thirty-one percent of all U.S. corn exported. Corn
exports to the EU went from $305 million in 1996 to $1 million in 1999 because of GMO
restrictions. See id.




protection for plants, and several countries began to recognize that this
protection was necessary. 131 In 1961, the International Convention for the
Protection of New Varieties of Plants (UPOV) was adopted in Paris to
protect plant breeders' rights (PBRs).132
The United States passed the Plant Patent Law in 1930 to protect
asexually reproduced plants. 133  Forty years later, the Plant Variety
Protection Law gave protection to sexually reproduced varieties.' 34 "Both
of these laws had been passed in the belief that patent law did not extend
to living things."'135 However, a series of three landmark cases, beginning
with Diamond v. Chakrabarty136 in 1980, extended patent protection to
"biotechnological developments in microorganisms, plants, and higher life
forms.' 37 Because of these decisions, the United States offers perhaps the
most comprehensive coverage to biotech inventions of any nation.'
3 8
It is extremely interesting to note that the Chakrabarty patent
application was granted by the United Kingdom's patent office without
any opposition or controversy, while in the United States the patent was
fought to the Supreme Court .  Many Europeans believe that the United
States grants patents for a much broader scope than is allowed in the EU
or in its individual member nations. 40  Since the early 1980s, the
controversy surrounding patents for genetically engineered organisms has
faded in the United States and has greatly increased in Europe.
131 See id.
132 See id. at 123. To qualify for protection the new variety had to "be clearly
distinguishable by one or more important characteristics" and had to be "sufficiently
homogenous in its sexual reproduction." Id. The UPOV did not provide the same
protection as traditional patents. PBRs did not actually address whether "biological
?roducts" could be patented under traditional laws. Id.
" See id. at 126.
134See id.
13 id.
136 447 U.S. 303 (1980).
137 Purnell, supra note 15, at 1195 n.15. Chakrabarty extended protection to micro-
organisms. Exparte Hibbard, 227 U.S.P.Q. 443 (1985), held that plants, seeds and tissue
cultures are protectable. Finally, Ex parte Allen, 2 U.S.P.Q. 2d 1425, extended coverage
to higher organisms leading to the first animal patent on the "Harvard mouse." See id.
138 See Bosselmann, supra note 13, at 126.
139 See Yvonne Cripps, Aspects of Intellectual Property in Biotechnology: Some
European Legal Perspectives, in PROTECTION OF GLOBAL BIODIVERSITY, supra note 64,
at 316, 318.
'
40 See Ashworth, supra note 83, at 94.
141 See id. The EPC specifically excludes from protection any inventions that would be
contrary to morality if published or exploited. Patents on engineered plants have been
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The structure governing patent rights in the EU has much to do
with its opposition to biotechnology. In countries that are part of the
European Patent Convention (EPC), 142 patent applications may be made
through a member country's patent office, or under the EPC. The purpose
of the EPC was to enable an applicant seeking patent rights in more than
one European nation to achieve such result with only one application. 14
3
When a European patent is granted, its enforceability is determined by the
courts of the member countries, and thus is subject to over a dozen degrees
of protection.'" Thus, the EPC "accomplishes nothing toward the
unification of property rights, which is the most valuable element of a
patent convention.' 4  The EPC additionally contains a provision that
provides an opportunity for the public to challenge applications before
they issue as patents. 14  Through this means, the public has the ability to
delay or impede patents to which they are opposed.14
7
Since the 1980s, intellectual property rights have been considered
as a "barrier to free trade" by developed nations unless the lesser-
developed countries changed their intellectual property legislation to the
same level of protection. 14  Many underdeveloped nations believe that
patents provide a means for developed countries to stay ahead in
technology and to prevent the underdeveloped from forming any
substantial research and development (R&D) industry. 149 The developed
nations view patent protection as necessary to allow companies to recoup
what they have spent on R&D.15 0 In the biotechnology industry, large
opposed based on the assertion that plants and animals are "part of the common heritage
of humankind." Cripps, supra note 139, at 320.
142 Convention for the European Patent for the Common Market, Dec. 15, 1975, 15
I.L.M. 5. The member nations of the EPC include all members of the EU plus
Liechtenstein, Monaco, and Egypt. See Scalise & Nugent, supra note 68, at 1012.
143 See id.
'i4 See id. at 1013.
145 id.
'"See id. at 1014.
147 See id.
148 See Bosselmann, supra note 13, at 127.
149 See id; see also Powers, supra note 63, at 114. "Most developed nations, while
clearly perceiving the economic importance of intellectual property protection, regard the
protection of intellectual property as a fundamental right comparable to rights to physical
property. In most developing nations, by contrast, the protection of intellectual property
is viewed fundamentally as an economic policy question." Id. (quoting R. MICHAEL
GADBAW & TIMOTHY J. RICHARDS, INTELLECTUAL PROPERTY RIGHTS GLOBAL
CONSENSUS, GLOBAL CONFLICT? 2 (1988)).
150 See Bosselmann, supra note 13, at 127. The vast majority of biotech development
takes place in the private sector by large multi-national companies. The high costs of
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investments are required for relatively high-risk projects. A market for
innovation will not exist if exclusive rights are not granted. Those
obtaining patents in the United States cannot use them to prevent others
abroad from freely making or using the particular invention. If they wish
to protect their invention elsewhere, they will have to apply for a patent in
each nation where they desire protection. However, patentable subject
matter differs between nations. Enforcing intellectual property rights in
foreign nations could. reduce the trade deficit by increasing the
competitiveness of domestic products overseas.'51
Generally, the developing nations, with Mexico and Brazil as
exceptions, lack the type of intellectual property protection that is found in
the rest of the developed world.152  Intellectual rights granted by
developed nations are not enforced in the lesser-developed countries
because officials there tend to believe that granting monopolies to foreign
companies will hurt local economies.
153
In the past decade, treaties dealing with intellectual property have
been dominated by developed nations' attempts to protect their intellectual
property rights in developing countries.'54 Many believe that the "over-
protectionism" of the U.S. patent system has resulted in biopiracy.155
However, the underdeveloped nations contend that the gene-poor
developed nations are "robbing the gene-rich" developing nations "of
germplasm as a resource for biotechnology and then selling products such
as ...seeds back to the South for enormous profit."' Third-world
nations have few, if any, resources with which to acquire biotechnology.
However, access to biotechnology is of crucial importance to these nations
R&D will likely encourage the development of the most profitable projects. Thus, the
development of products desperately needed by third-world nations will necessarily take
a back seat. See Purnell, supra note 15, at 1201.
"' Enforcing IP rights will increase the price of foreign goods to cover royalties that
foreign manufacturers must pay and will decrease the quality of foreign goods by
denying foreign manufacturers access to protected U.S. technology.
152 See Powers, supra note 63, at 116-17.
"' See id. at 117.
154 See Alan Story, Biopiracy and the Dangers of Patent Over-Protection, 149 NEw L.J.
158, 158 (1999).
155 "Biopiracy" is the appropriation and propertization, without permission, of the rich
resources most commonly found in developing nations. The over-protectionism of the
U.S. patent system, where most of the pirated products have been granted a patent, has
exacerbated the problem, many believe. Patenting stolen wealth creates a financial
incentive for richer nations to pirate third-world biological wealth. See id. The failure of
foreign countries to enforce U.S. patents results in lost royalties. See Purnell, supra note
15, at 1199.
156 Bosselmann, supra note 13, at 132.
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in order to solve the many environmental and health related problems that
they face. 1
57
There is a connection between biodiversity and intellectual
property law. Some fear that the limited monopolies which are conferred
by patents will cause a loss of genetic diversity by encouraging industry to
focus on genetically engineered plants and not organisms that offer fewer
genetic advantages.15 8 However, genetic diversity may also be enhanced
by the patent system because a financial incentive is created to produce
new genotypes. 159  Additionally, to satisfy the patent disclosure
requirements, a sample of the biological material must be deposited.
60
These depositories will save genetic material that may not otherwise exist
in the future. 16
1
V. CONVENTION ON BIOLOGICAL DIVERSITY
"In 1992, 178 nations met.., for the Earth Summit," to discuss,
among other issues, the conservation of biological diversity. 162 The
United Nations Convention on Biological Diversity (Convention) was one
document that resulted from that meeting. 63  The Convention is an
agreement that builds upon earlier treaties and attempts to deal with
biodiversity in a more comprehensive manner. 164 The specific objectives
of the Convention are "the conservation of biological diversity, the
sustainable use of its components and the [flair [sic] and equitable sharing
of the benefits arising out of the utilization of genetic resources."' 65 Many
developed nations had reservations over signing the document and did so
stating that they would interpret it individually. 166 The wording of the
Convention is vague and thus it is unknown what the impact will be.167
157 See Purnell, supra note 15, at 1200.
158 See Cripps, supra note 139, at 317.59 See id.
160 See id.
161 See id.
162 Purnell, supra note 15, at 1202.
163 See Convention, supra note 8. The Convention was adopted on May 22, 1992 and
entered into force on Dec. 29, 1993. There are currently 175 parties to the Convention.
See Purnell, supra note 15, at 1202.164 See Daniel M. Bodansky, International Law and the Protection of Biological
Diversity, 28 VAND. J. TRANSNAT'L L. 623, 630 (1995).
165 Convention, supra note 8, at art. 1.
'6 See Bossehnann, supra note 13, at 136-37. The United States signed the Convention
on the last day it was open for signature. See id.
167 See id. at 136.
740 [Vol. 25:721
AGRICULTURAL BIOTECHNOLOGY
This disagreement in interpretation raises concerns that the Convention
will not prove useful.168
One function of the Convention "is to allow countries where
biological resources are found to realize or recapture some of the value of
those resources."' 69 The Convention aims to provide payment for genetic
resources and to increase the ability of developing countries to develop
their own genetic resources. 170
Aside from social and economic considerations, the Convention
requires each member to take part in in-situ conservation.' 71 As per this
mandate, the countries with the greatest biological diversity will have the
largest economic burden to maintain it. 172
One of the most controversial parts of the Convention is the effect
that Articles 15, 16, and 19 may have on intellectual property rights. 173
Article 15 governs access to genetic resources.' 74  It states that "the
authority to determine access to genetic resources rests with the national
governments and is subject to national legislation."'' 7 5 Those nations with
genetic resources must facilitate access by other nations. 176  In return,
those countries or private companies seeking to utilize the resources must
take measures to share in a "fair and equitable way" the benefits arising
from the R&D of those resources. 177 Historically, genetic material has
been considered to be in the public domain, which is why industrialized
countries take genetic resources from third-world countries with no
See id. at 137.169 Bodansky, supra note 164, at 626-27; see Purnell, supra note 15, at 1203.
o70 See Powers, supra note 63, at 104. By providing these incentives, the Convention
hopes that the developing nations will preserve their tropical rainforests. See id.
171 'In-situ conditions' means conditions where genetic resources
exist within ecosystems and natural habitats, and, in the case
of domesticated or cultivated species, in the surroundings
where they have developed their distinctive properties. 'In-
situ conservation' means the conservation of ecosystems and
natural habitats and the maintenance and recovery of viable
populations of species in their natural surroundings and, in the
case of domesticated or cultivated species, in the surroundings
where they have developed their distinctive properties.
Convention, supra note 8, at art. 2.
172 See Powers, supra note 63, at 108 n.31 (estimating that the cost of preserving world-
wide biological diversity is approximately 50 billion dollars) (citation omitted).
173 See id. at 110.
17 Convention, supra note 8, at art. 15.
75 id.
17 6 See id. at 2.
'" Id. at 7.
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compensation in return.17 8 Article 15 however acknowledges a country's
right to direct compensation for materials taken and to part of the income
generated from any resulting products. 179  This is an extremely large
change in property rights to naturally occurring species.'80
Article 16 promotes access to and transfer of technology derived
from the research and development of genetic material.18' The Article
states that "both access to and transfer of technology among Contracting
Parties are essential elements for the attainment of the objectives of this
Convention."' 8 2  Contracting parties must pass legislation to grant
provider countries rights to the technology that makes use of the genetic
material. In this way intellectual property rights in the technology in
question will not interfere with the transfer of the technology. 83 Article
16 will likely cause complex negotiations in the future.
Article 19 further impacts intellectual property rights in
biotechnology by "requiring participating countries to pass legislation
guaranteeing that biotech companies share the results and benefits of their
research and development with genetic resource provider countries."'
8 4
Such legislation should serve to include provider countries in the
biotechnology research.' 8 5
178 See Powers, supra note 63, at 111.
179 See id.
0 See id.
181 See Convention, supra note 8, at art. 16.
182 Id. at art.16, 1.
3 See id. at art.16, 3 and 5. Article 16 states:
Each Contracting Party shall take legislative, administrative or policy
measures, as appropriate, with the aim that Contracting Parties, in
particular those that are developing countries, which provide genetic
resources are provided access to and transfer of technology which
makes use of those resources, on mutually agreed terms, including
technology protected by patents and other intellectual property rights..
... The Contracting Parties, recognizing that patents and other
intellectual property rights may have an influence on the
implementation of this Convention, shall cooperate in this regard
subject to national legislation and international law in order to ensure
that such rights are supportive of and do not run counter to its
objectives.
Id. at art.16, N 3 and 5.
184 Powers, supra note 63, at 112.-
185 See Convention, supra note 8, at art.19, 1. "Each Contracting Party shall take
legislative, administrative or policy measures, as appropriate, to provide for the effective
participation in biotechnological research activities by those Contracting Parties,
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Full compliance with the convention will essentially mean that a
company wanting another country's genetic resources "will have to give
up a portion of their intellectual property rights."' 86 The United States and
the EU nations will likely weaken these articles through interpretation.
The difference in economic and technological positions of the developed
and underdeveloped nations has caused the split in positions on the
intellectual property provisions.' 87 Additionally, protection of intellectual
property is vastly different between these two sets of countries. The
United States' tradition has been to increase the intellectual property rights
in biotechnology.
It is not yet clear how intellectual property rights on a global scale
may be affected by the Convention. Such effect mainly depends on
legislation passed by each individual member nation. Clearly, however,
erosion of intellectual property rights will only serve as a disincentive to
biotech companies to conduct future research. 8 8 The particular types of
genetically engineered products to be covered by provisions of the
Convention are in dispute. The United States and other major agricultural
exporters wish to restrict the scope of the Biosafety Protocol to GMOs that
would be introduced into the environment, such as seeds.' 89 Generally,
developing countries seek a broader definition that would include GMOs
that are "agricultural commodities or that are used for food, animal feed,
or processing."' 90 Such rules would radically impede international trade
without providing a benefit to the environment.' 9' The United States has
especially developing countries, which provide the genetic resources for such research..
. ." Id.
196 Powers, supra note 63, at 118.
17 See id. at 113.
.88 See id. at 119.
189 See Andrew Pollack, Setting Rules for Biotechnology Trade, N.Y. TIMES, Feb. 15,
1999, at A8. Several negotiating groups have formed as negotiations continue. These are
the EU, the Central and Eastern European countries, the Developing Countries, the
Miami Group of Major Agricultural Exporters (Argentina, Australia, Canada, Chile,
Uruguay, and the United States), and the Compromise Group (Japan, Korea, Mexico,
Norway & Switzerland). See Summary Points on the Upcoming Montreal Biosafety
Negotiations, at http://usinfo.state/gov/topical/global/biotech/0001 1800.htm (Jan. 1,
2000).
'90 Jim Fuller, Negotiators Meet in Montreal to Finalize Biosafety Protocol, at
http://usinfo.state.gov/topical/global/biotech/00011304.htm (Jan. 13, 2000).
191 The Advanced Informed Agreement (AIA) is a procedure defined by the protocol to
notify countries prior to shipments of GMOs. The United States takes the position that an
AIA applied to things such as commodities, which will not be introduced into the
environment, would be impractical. Bulk commodities are shipped in very large
quantities and often mixed together at different stops. Thus the only way to implement
2001) 743
WM. & MARY ENVTL. L. & POL'Y REV.
accused Europe of wanting a treaty which will aid it in erecting trade
barriers in order to justify the tight position is has taken on GMOs. The
United States also seeks to ensure that the treaty does not take precedence
over the WTO rules.1
92
Negotiations of the Biosafety Protocol, an outgrowth of the
Convention, began in 1999 in an effort to regulate the trade of genetically
modified foods. 193 The United States never ratified the Convention but
has been able to take part in negotiations.1 94 More than 130 nations
adopted the treaty on January 29, 2000 in Montreal.'95 It will be known as
the Cartagena Protocol on Biosafety and allows countries to prohibit the
import of GMOs that they believe are a threat to their environment.
196
Most of the proposed provisions which the United States stringently
opposed were diluted or eliminated altogether.' 97  The primary
requirement of the treaty is that "exporters must obtain permission in
advance from the importing country before the first shipment of a
an AIA procedure would be to segregate shipments, an action which would require
massive investments in infrastructure. The Biodiversity Convention is an environmental
agreement and as such should not deal with issues such as food safety or trade. See id.
192 See Andrew Pollack, Talks on Biotech Food Today in Montreal Will See US. Isolated,
N.Y. TIMES, Jan. 24, 2000, at A10.
193 See US., Developing Nations Quarrel over Biotech Pact, DESERT NEWS (Salt Lake
City, UT), Feb. 23, 1999, at A5. The first session of talks on the Biosafety Protocol was
held in February 1999 in Cartagena, Columbia, with talks reaching a stalemate over sharp
disagreements between the United States and most developing countries. The United
States and five other grain exporting nations rejected a proposal that would have required
exporters of genetically modified crops to obtain advance permission from the importing
nation. See Report of the 6h Session of the Open Ended Ad Hoc Working Group on
Biosafety and the I" Extraordinary Session of the CBD Conference of the Parties, 9
EARTH NEGOTIATIONS BULL. 117. Two informal sessions were held in July and
September 1999. Discussions were scheduled to resume on Jan. 20, 2000, in Montreal.
See Fuller, supra note 190.
194 See Pollack, supra note 189. The Bush administration opposed the Convention on the
grounds that it would undermine the protection granted by the U.S. patent system for
biotechnology. See Krimsky, supra note 19, at 224. The United States' allies at the talks
are Argentina, Australia, Canada, Chile and Uruguay. Because the United States never
ratified the Convention, it cannot be a part of the biosafety protocol. However, the
United States will have to comply with its rules when exporting to nations who are
parties. See Pollack, supra note 192, at A10.
9 See Andrew Pollack, 130 Nations Agree on Safety Rules for Biotech Food, N.Y.








particular 'living modified organism' meant for release into the
environment.' 98  One evident problem with the terms of the protocol is
that a nation can bar the import of a GMO even if there is no scientific
proof that it is dangerous.
VI. OTHER OPTIONS
Contractual obligations are another way in which third-world
nations could be reimbursed for their resources. 199 In one form of
contractual agreement the undeveloped nations would essentially sell their
germplasm for "payment and/or royalties on future sales." 200 This income
could then be used to conserve areas of biodiversity. 20 1  Some
multinational companies have already made such agreements.20 2 The
contract between pharmaceutical company Merck and Costa Rica is a
model agreement that should be followed by others. Perhaps the most
important aspect of the Merck/Costa Rica agreement is that Merck will
retain all intellectual rights to any products developed as a part of this
research.203 Additionally important for Costa Rica is that the genetic
diversity of their forests will finance their own preservation. 204 This
agreement should lead the way in providing compensation for genetic
resources.
205
198 Id. Notice will not be required "for exports of agricultural commodities meant for
eating or processing rather than for release into the environment." Id.
'99 See Bodansky, supra note 164, at 630.200 Bosselmann, supra note 13, at 142.
201 If farmers do not recognize that the forest has value, the outlook for preservation is
om. See Pollack, supra note 195, at Al.
In 1991, the pharmaceutical firm Merck entered into'a "prospecting" agreement with
Costa Rica. Under the agreement, a non-profit organization created by the Costa Rican
government was to provide 10,000 germplasm samples to Merck. Merck would in return
pay one million dollars, provide equipment, training, and a certain amount of technology
transfer, and pay a royalty on the sale of any drugs produced from the samples. The
Costa Rican organization was also to contribute to conservation efforts. See id.; see also
Powers, supra note 63, at 121.203 See Powers, supra note 63, at 121.
204 See id. at 122. Merck received environmental achievement awards from the National
Wildlife Foundation and the National Environmental Development Association. Id.205 The market solution, illustrated by the Merck agreement, is not free of possible
drawbacks. Infringement could be hard to detect, and even if discovered the costs of
bringing an action may be prohibitive. Additionally, not every chemical is valuable and
as such the market may not provide adequate compensation to the lesser developed
nations. See Bosselmann, supra note 13, at 143-44.
2001] 745
WM. & MARY ENVTL. L. & POL'Y REV.
However, the future of these types of contractual agreements is far
from predictable. Many developing countries, angry that they have not
profited from their own resources, have began restricting the freedom of
scientists to collect samples and are demanding payment for permits to do
so. 20 6  Since the Convention on Biological Diversity established that
"nations have sovereignty over their genetic resources," many nations
have adopted laws controlling access to such resources.20 7 One obstacle is
that many nations overestimate the value of their genetic resources. 20 8 If
the developing nations exclude researchers, nobody wins. They must be
reasonable in their expectations of compensation and be willing to
compromise.
VII. CONCLUSION
A danger exists that ongoing disputes over biotechnology issues
will so polarize the interested countries that it will become impossible for
developing countries to gain anything from the technology. These nations
are most needy of the genetically engineered products produced by both
America and multi-national countries, and developed nations need
biodiversity to be preserved. If developing nations are to preserve genetic
resources, they must have an incentive for doing so. The developed
nations have the means to provide such an incentive.
As an increasing number of developing countries are investing
resources in biotech research, it is most important to create conditions
which will enable them to take full advantage of their opportunities.20 9
Many sources of funding exist for biotechnology programs in developing
nations.21 0 Such relationships must be encouraged and more funding
206 See Andrew Pollack, Patenting Life: A Special Report: Biological Products Raise
Genetic Ownership Issues, N.Y. TIMES, Nov. 26, 1999, at Al.207 id.
208 See id. Drug development can cost millions of dollars and span one to two decades.
The NIH, for example, has collected 50,000 plants from thirty countries over the last
fifteen years and has only one drug in clinical trials. It is thus hard to determine how
much money a country should get just because the starting plant for research was taken
from its territory. See id.
209 See Carliene Brenner, Biotechnology Policy for Developing Country Agriculture,
1997, at http://www.oecd.org/dev/ENGLISH/publication/Policy-B/pbl4a.pdf (last visited
Feb. 27, 2001).
210 Some sources of funding are international organizations, national agriculture research
institutions, universities, private foundations, commercial companies, and bilateral and
multilateral aid agencies. See Brenner & Komen, supra note 30, at 24.
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provided.2 1' GMOs provide much hope for the problems faced by the
third-world nations. They will boost nutritional value of crops, reduce the
need for pesticides, reduce the need to till soil, improve yields, and
increase drought resistance of plants. Concerns continue however that
developing countries will be denied free access to modified plants. Only
if a worldwide agreement is reached, will biotechnology realize its full
potential.
The benefits of agricultural biotechnology are quite impressive.
This new technology, like any other, does have risks, but the bulk of fears
are fears of the unknown. Careful, but not oppressive, monitoring by
regulatory agencies with the cooperation of the companies producing the
seeds and the farmers planting them, will keep the known risks from
becoming problems. The EU particularly needs to change its regulatory
policies and recognize the benefits of agricultural biotechnology.
While the Biodiversity Convention has an important goal, its
objectives are not likely to be met in the manner desired by the text. Its
potential erosion of the intellectual property rights, which the United
States particularly sees as fundamental, will be the cause. The developed
countries do need to give back to those nations from which they take
genetic resources. However, such reimbursement can occur in ways other
than property rights; U.S. companies have already shown that such means
do exist.
Biotechnology is not the panacea, but it is perhaps the best tool
that is available today. It can aid third-world nations, preserve
biodiversity, and increase the food supply for the developed nations. As
the world population increases, biotechnology provides the only current
answer to solving food shortages. If the EU and other nations of the world
do not embrace this technology, they will not be able to feed themselves
one day. The unwarranted opposition to GMOs by the EU, and most
recently by Japan, because of their trading relationship with the United
States, threatens the existence of GMOs on a global scale. If import
restrictions become severe and/or widespread, the United States will be
prohibited from growing genetically modified crops. If the United States
is not growing these crops, U.S. biotech companies will have no incentive
211 A model relationship exists between Monsanto Chemical Co. and Kenya. Monsanto
proposed its idea to the U.S. Agency for International Development (USAID), an
organization which funds biotechnology research, who agreed to contribute. Monsanto
will provide three years of post doctoral training in techniques of genetic transformation
of the sweet potato into a virus resistant variety. Monsanto also provides a royalty-free
non-exclusive license and additional funding to the Kenyan Agricultural Research
Institute to develop this technology. See id. at 40.
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to continue researching and developing GMOs. The outcome of this chain
of events will be that the developing nations will be denied the great
benefits of genetically altered crops.
